I appreciate your comments and feedback i try not to make Sh--...

I appreciate your comments and feedback i try not to make Sh-- up and follow the news and announcements from the company, however being a long time investor and knowing that new drug development is a risky business and take a long time to achieve success, Noxopharm unlike other companies are using the resources of universities like the UNSW where the university have already spent lots of money and many years working on the drug and Noxopharm is fine tunning to the finish line, the same as our collaboration with the Hudson institute.

The fact that management is holding off on a capital raise tells me that management is confident that they may be able to close a deal before they run out of money.

Also the Ionic trial Under the supervision of Professor Paul de Souza, this trial commenced in March 2021 and is ongoing across several Australian sites, to have this trial still continuing after 3 years tells me that they are seeing some positive outcomes as Noxopharm is not shy of closing trials when they see that there might be No positive outcome .

This was reported at ASCO on 26 may 2023

From the trial at ASCO ; complete response (CR) in 2 pts, both with ongoing CR at 24 weeks.

Conclusions:Preliminary analysis shows promising tumour responses from the combination therapy which appears to be well-tolerated, with no safety signals evident to date. Clinical trial information: ACTRN12621001537842.